Exploring the Molecular Mechanism of Action of Yinchen Wuling Powder for the Treatment of Hyperlipidemia, Using Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
03
2021
accepted:
27
09
2021
entrez:
8
11
2021
pubmed:
9
11
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Yinchen Wuling powder is often used to treat clinical hyperlipidemia, although its mechanism of action remains unclear. In this study, we aimed to investigate the active ingredients found in Yinchen Wuling powder and find its mechanism of action when treating hyperlipidemia, using a combination of network pharmacology, molecular docking, and molecular dynamics simulation approaches. The TCMSP database was used to obtain the principle active ingredients found in Yinchen Wuling powder and the NCBI and DisGeNet databases were used to obtain the main target genes involved in hyperlipidemia, and the intersectional targets were obtained by EXCEL. We also used Cytoscape 3.7.2 software to construct a "Traditional Chinese Medicine-Active Ingredient-Target" network and use STRING platform to conduct "protein-protein interactional" (PPI) analyses on the intersection targets. Bioconductor software and RX 64 4.0.0 software were then used to perform GO functional enrichment analysis and KEGG pathway enrichment analysis on the targets. Molecular docking of core protein-ligand interactions was modeled using AutoDock Vina software. A simulation of molecular dynamics was conducted for the optimal core protein-ligand obtained by molecular docking using Amber18 software. A total of 63 active ingredients were found in Yinchen Wuling powder, corresponding to 175 targets, 508 hyperlipidemia targets, and 55 intersection targets in total. Cytoscape 3.7.2 showed that the key active ingredients were quercetin, isorhamnetin, taxifolin, demethoxycapillarisin, and artepillin A. The PPI network showed that the key proteins involved were AKT1, IL6, VEGFA, and PTGS2. GO enrichment analysis found that genes were enriched primarily in response to oxygen levels and nutrient levels of the vesicular lumen and were associated with membrane rafts. These were mainly enriched in AGE-RAGE (advanced glycation end products-receptor for advanced glycation end products) signaling pathway in diabetic complications, fluid shear stress, and atherosclerosis, as well as other pathways. The molecular docking results indicated key binding activity between PTGS2-quercetin, PTGS2-isorhamnetin, and PTGS2-taxifolin. Results from molecular dynamics simulations showed that PTGS2-quercetin, PTGS2-isorhamnetin, and PTGS2-taxifolin bound more stably, and their binding free energies were PTGS2-quercetin -29.5 kcal/mol, PTGS2-isorhamnetin -32 kcal/mol, and PTGS2-taxifolin -32.9 kcal/mol. This study is based on network pharmacology and reveals the potential molecular mechanisms involved in the treatment of hyperlipidemia by Yinchen Wuling powder.
Sections du résumé
BACKGROUND
BACKGROUND
Yinchen Wuling powder is often used to treat clinical hyperlipidemia, although its mechanism of action remains unclear. In this study, we aimed to investigate the active ingredients found in Yinchen Wuling powder and find its mechanism of action when treating hyperlipidemia, using a combination of network pharmacology, molecular docking, and molecular dynamics simulation approaches.
METHODS
METHODS
The TCMSP database was used to obtain the principle active ingredients found in Yinchen Wuling powder and the NCBI and DisGeNet databases were used to obtain the main target genes involved in hyperlipidemia, and the intersectional targets were obtained by EXCEL. We also used Cytoscape 3.7.2 software to construct a "Traditional Chinese Medicine-Active Ingredient-Target" network and use STRING platform to conduct "protein-protein interactional" (PPI) analyses on the intersection targets. Bioconductor software and RX 64 4.0.0 software were then used to perform GO functional enrichment analysis and KEGG pathway enrichment analysis on the targets. Molecular docking of core protein-ligand interactions was modeled using AutoDock Vina software. A simulation of molecular dynamics was conducted for the optimal core protein-ligand obtained by molecular docking using Amber18 software.
RESULTS
RESULTS
A total of 63 active ingredients were found in Yinchen Wuling powder, corresponding to 175 targets, 508 hyperlipidemia targets, and 55 intersection targets in total. Cytoscape 3.7.2 showed that the key active ingredients were quercetin, isorhamnetin, taxifolin, demethoxycapillarisin, and artepillin A. The PPI network showed that the key proteins involved were AKT1, IL6, VEGFA, and PTGS2. GO enrichment analysis found that genes were enriched primarily in response to oxygen levels and nutrient levels of the vesicular lumen and were associated with membrane rafts. These were mainly enriched in AGE-RAGE (advanced glycation end products-receptor for advanced glycation end products) signaling pathway in diabetic complications, fluid shear stress, and atherosclerosis, as well as other pathways. The molecular docking results indicated key binding activity between PTGS2-quercetin, PTGS2-isorhamnetin, and PTGS2-taxifolin. Results from molecular dynamics simulations showed that PTGS2-quercetin, PTGS2-isorhamnetin, and PTGS2-taxifolin bound more stably, and their binding free energies were PTGS2-quercetin -29.5 kcal/mol, PTGS2-isorhamnetin -32 kcal/mol, and PTGS2-taxifolin -32.9 kcal/mol.
CONCLUSION
CONCLUSIONS
This study is based on network pharmacology and reveals the potential molecular mechanisms involved in the treatment of hyperlipidemia by Yinchen Wuling powder.
Identifiants
pubmed: 34746316
doi: 10.1155/2021/9965906
pmc: PMC8568510
doi:
Substances chimiques
Drugs, Chinese Herbal
0
wuling
0
yinchen
0
yinchenwuling
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9965906Informations de copyright
Copyright © 2021 Jiahao Ye et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Food Chem Toxicol. 2014 Jan;63:221-32
pubmed: 24269735
Zhongguo Zhong Yao Za Zhi. 2017 Feb;42(3):531-535
pubmed: 28952260
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Placenta. 1988 Jan-Feb;9(1):95-108
pubmed: 3283724
Biomol Ther (Seoul). 2014 Jan;22(1):47-54
pubmed: 24596621
Cardiovasc Res. 2004 Sep 1;63(4):582-92
pubmed: 15306213
Biochemistry (Mosc). 2009 Mar;74(3):301-7
pubmed: 19364325
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Mol Cell Oncol. 2015 Jul 07;2(4):e980184
pubmed: 27308514
Front Pharmacol. 2017 Aug 03;8:464
pubmed: 28824425
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006 Apr;18(4):233-6
pubmed: 16647016
Phytomedicine. 2019 Feb;53:43-52
pubmed: 30668411
J Cheminform. 2014 Apr 16;6:13
pubmed: 24735618
Lipids Health Dis. 2017 Jan 14;16(1):9
pubmed: 28088205
Eur J Pharmacol. 2010 Dec 1;648(1-3):39-49
pubmed: 20816811
Medicine (Baltimore). 2018 Nov;97(44):e13048
pubmed: 30383674
Int J Mol Sci. 2015 Nov 02;16(11):26151-65
pubmed: 26540043
J Biomed Sci. 2006 Jan;13(1):127-41
pubmed: 16283433
Cells. 2019 Mar 03;8(3):
pubmed: 30832409
Food Chem. 2013 Nov 15;141(2):723-30
pubmed: 23790840
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Stroke. 2009 Aug;40(8):2945-8
pubmed: 19478221
Saudi Med J. 2011 Jul;32(7):701-7
pubmed: 21748207
Evid Based Complement Alternat Med. 2016;2016:4753852
pubmed: 27872650
Int J Biol Sci. 2018 Aug 6;14(11):1483-1496
pubmed: 30263000
Genome Biol. 2019 Sep 2;20(1):185
pubmed: 31477170
FEBS Open Bio. 2014 Sep 02;4:755-62
pubmed: 25349780
PLoS One. 2019 Mar 28;14(3):e0214332
pubmed: 30921378
PeerJ. 2019 Jan 31;7:e6383
pubmed: 30723634
Chin Med. 2009 Mar 26;4:5
pubmed: 19321011
Int J Endocrinol. 2019 Sep 18;2019:2151302
pubmed: 31641351
Circulation. 2004 Sep 7;110(10):1330-6
pubmed: 15313955
BMC Bioinformatics. 2003 Jan 13;4:2
pubmed: 12525261